Login / Signup

A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer.

Yuchen GuoYangyang ZhouWenxin Qin
Published in: Cancer biology & medicine (2021)
Keyphrases
  • epidermal growth factor receptor
  • crispr cas
  • tyrosine kinase
  • advanced non small cell lung cancer
  • genome editing
  • high throughput
  • combination therapy